Agenus, Inc. (AGEN)
6.33
-0.18
(-2.76%)
USD |
NASDAQ |
Oct 23, 16:00
6.32
-0.01
(-0.16%)
After-Hours: 20:00
Agenus Enterprise Value : 534.42M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 534.42M |
| October 22, 2026 | 542.09M |
| October 21, 2026 | 537.40M |
| October 20, 2026 | 538.25M |
| October 19, 2026 | 528.02M |
| October 16, 2026 | 522.06M |
| October 15, 2026 | 549.33M |
| October 14, 2026 | 541.66M |
| October 13, 2026 | 560.84M |
| October 12, 2026 | 581.29M |
| October 09, 2026 | 591.52M |
| October 08, 2026 | 585.98M |
| October 07, 2026 | 587.26M |
| October 06, 2026 | 583.85M |
| October 05, 2026 | 636.69M |
| October 02, 2026 | 620.93M |
| October 01, 2026 | 619.65M |
| September 30, 2026 | 687.83M |
| September 29, 2026 | 686.13M |
| September 28, 2026 | 666.53M |
| September 25, 2026 | 628.60M |
| September 24, 2026 | 626.89M |
| September 23, 2026 | 622.63M |
| September 22, 2026 | 635.42M |
| September 21, 2026 | 619.65M |
| Date | Value |
|---|---|
| September 18, 2026 | 599.19M |
| September 17, 2026 | 572.34M |
| September 16, 2026 | 571.92M |
| September 15, 2026 | 569.79M |
| September 14, 2026 | 568.51M |
| September 11, 2026 | 560.41M |
| September 10, 2026 | 558.28M |
| September 09, 2026 | 557.00M |
| September 08, 2026 | 581.29M |
| September 04, 2026 | 615.81M |
| September 03, 2026 | 615.81M |
| September 02, 2026 | 609.42M |
| September 01, 2026 | 605.16M |
| August 31, 2026 | 588.96M |
| August 28, 2026 | 591.10M |
| August 27, 2026 | 597.49M |
| August 26, 2026 | 616.24M |
| August 25, 2026 | 620.93M |
| August 24, 2026 | 591.52M |
| August 21, 2026 | 609.42M |
| August 20, 2026 | 583.85M |
| August 19, 2026 | 616.66M |
| August 18, 2026 | 585.56M |
| August 17, 2026 | 569.36M |
| August 14, 2026 | 576.61M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Halozyme Therapeutics, Inc. | 16.24B |
| AVITA Medical, Inc. | 517.02M |
| Iovance Biotherapeutics, Inc. | 6.131B |
| Amgen, Inc. | 280.78B |
| Anika Therapeutics, Inc. | 273.50M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.567M |
| Revenue (Quarterly) | 34.52M |
| Total Expenses (Quarterly) | 35.07M |
| EPS Diluted (Quarterly) | -0.0146 |
| Gross Profit Margin (Quarterly) | 98.50% |
| Profit Margin (Quarterly) | -1.64% |
| Earnings Yield | 41.88% |
| Operating Earnings Yield | 15.34% |
| Normalized Earnings Yield | 15.77 |